<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354886</url>
  </required_header>
  <id_info>
    <org_study_id>GEXGP240101</org_study_id>
    <nct_id>NCT01354886</nct_id>
  </id_info>
  <brief_title>Single Dose FSH-GEX™ in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Monocenter, Randomized, Placebo and Comparator Controlled, Single Blind, Rising Dose, Clinical Study to Determine Single Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Four Doses of FSH-GEX™ According to Adaptive Design (25, 75, 150 and 300 IU) Administered Subcutaneously in Healthy Pituitary-suppressed Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycotope Biotechnology GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is the pharmacokinetic and pharmacodynamic characterization of a
      single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female
      volunteers, in comparison with two marketed comparator products.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to assess the safety and (local) tolerability of FSH-GEX™ following single rising dose administration by subcutaneous injection</measure>
    <description>frequency of dose related adverse events, measurement of vital signs, body measurements, transvaginal ultrasound, ECG and laboratory values in comparison to placebo and the two comparators with marketing authorization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine FSH pharmacokinetic parameters of FSH-GEX™ following single dose administration by subcutaneous injection (part 1)</measure>
    <description>C(max)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine FSH pharmacokinetic parameters of FSH-GEX™ following single dose administration by subcutaneous injection (part 2)</measure>
    <description>AUC(0-last)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the pharmacodynamic effect of FSH-GEX™ following single rising dose administration by subcutaneous injection (part 1)</measure>
    <description>determined by Estradiol (E2) and inhibin B concentrations depending on dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the pharmacodynamic effect of FSH-GEX™ following single rising dose administration by subcutaneous injection (part 2)</measure>
    <description>ovarian follicle number and size as determined by transvaginal ultrasonography depending on dose</description>
  </secondary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Female Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH-GEX™</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator 1</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator 2</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female subjects from 18-40 years of age.

          2. Subjects must be in good health.

          3. Subjects must be willing to use additional non-hormonal contraception

          4. Subjects must have used a COC for at least one cycle.

          5. Vital signs which are within the following ranges at baseline measurements: systolic
             blood pressure of 90-140 mmHg, diastolic blood pressure of 50-90 mmHg and pulse rate
             of 40 - 100 bpm.

          6. Subjects must have a body weight of minmally 50.0 kg with a BMI between 18.0 and 29.0
             kg/m^2 at baseline measurements.

          7. Able to provide written informed consent prior to study participation.

          8. Able to communicate well with the investigator and to understand and comply with the
             requirements of the study.

        Exclusion Criteria:

          1. Smokers of more than 10 cigarettes per day.

          2. Average daily intake of more than 3 units of alcohol per day or an average weekly
             intake of more than 21 units alcohol.

          3. Use of any prescription drug or OTC medication from screening until the end-of-study
             visit, without prior approval of the investigator.

          4. Any drugs thay may reduce the effectiveness of COC from screening until the
             end-of-study visit.

          5. Any FSH preparation within 90 days prior to screening.

          6. Administration of any investigational product or use of any investigational device
             within 30 days prior to screening.

          7. Donation or loss of 500 mL or more blood within 90 days prior to first FSH-GEX™
             dosing.

          8. History of acute or chronic bronchospastic disease (including asthma and chronic
             obstructive pulmonary disease, treated or not treated).

          9. History of allergies for drugs, seafood, nuts, eggs, wasp-stings; history of atopic
             allergy (asthma, urticaria, eczematous dermatitis). A known hypertensitivity to any of
             the study drugs.

         10. Any surgical or medical condition which might alter the absorption, distribution,
             metabolism, or excretion of drugs or which may jeopardize the subject in case of
             participation in the study.

         11. History or presence of any malignancy.

         12. Determined or suspected pregnancy.

         13. Breast feeding women.

         14. History of (or current) endocrine abnomalities.

         15. Contraindication for the use of oral contraceptives.

         16. Contraindication for the use of follitropin alfa, follicle-stimulating hormone (FSH)
             or any of the excipients (hypersensitivity to follitropin alfa, FSH or any of the
             excipients; tumors of the hypothalamus or the pituitary gland; ovarian enlargement or
             cyst not due to polycystic ovarian disease; gynecological bleeding of unknown origin;
             ovarian, uterine, or mammary carcinoma).

         17. Porphyria or family history of porphyria.

         18. History of ovarian surgery.

         19. Any ovarian or abdominal abnormality that would interfere with adequate ultrasound
             investigation.

         20. An abnormal cervical smear.

         21. History or presence of an immune-compromising disease, or a positive human
             immunodeficiency virus (HIV) test result in the past or at the screening visit.

         22. History of Hepatitis B or C, or a positive Hepatitis B surface antigen (HBsAg) or
             Hepatitis C test result at the screening visit.

         23. History of drug or alcohol abuse within the 12 months prior to the screening visit or
             evidence of such abuse.

         24. Planned surgery or hospitalization during the period of the study.

         25. Concurrent participation or participation within 30 days before screening in another
             clinical trial, or participation in more than 3 clinical studies within 12 months,
             prior to the expected date of enrolment into the study.

         26. Injection of one or more doses of any depot contraceptive drug /drug combination or
             hormonal implants &lt;= 10 months prior to screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glycotope GmbH</last_name>
    <role>Study Director</role>
    <affiliation>Glycotope GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>November 25, 2011</last_update_submitted>
  <last_update_submitted_qc>November 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Glycotope GmbH, Study Director</name_title>
    <organization>Glycotope GmbH</organization>
  </responsible_party>
  <keyword>in-vitro fertilization</keyword>
  <keyword>reproductive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

